CGON News and Press, CG Oncology, Inc. From 12/05/25

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with optimized administration Robust...

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladde...

IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced t wo late breaking pod...

2025-11-24 07:51:54 ET Gregory Renza from Truist Financial issued a price target of $62.00 for CGON on 2025-11-24 12:36:09. The adjusted price target was set to $62.00. At the time of the announcement, CGON was trading at $42.44. The overall price target consensus is at ...

2025-11-14 08:20:21 ET More on CG Oncology CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) ClearBridge Small Cap Strategy adds KWR, RNA, exits ...

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in-disease durability and tolerability in BOND-003 Cohort C with robust 24-...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

2025-10-15 12:18:25 ET More on LXP Industrial Trust, Wabash National, etc. Freshpet: Still Barking At A Potential Bargain GoodRx: Novo Deal And TrumpRx Talks Point To Ebitda/FCF Upside CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? GoodRx l...

2025-10-13 11:15:14 ET More on related tickers Kratos Defense: High Hopes In Unmanned Tech, But Valuation Clouds Near-Term Upside CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? Oscar Health: What The U.S. Government Shutdown Means To The Company ...

2025-10-09 15:48:12 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?